Navigation Links
EHRA-AFNET summit on AF
Date:6/23/2008

Seeking to set the agenda for urgent research in the field of Atrial Fibrillation, cardiologists from Europe and beyond will meet on 26 October 2008, at the European Heart House, headquarters of the European Society of Cardiology1.

Atrial Fibrillation (AF) affects several million people in the European Union. Its incidence increases in an ageing population. It is estimated that one in four 40 year olds will develop AF during his or her life2 .Consequences of AF are diverse, ranging from severe limitations of exercise capacity to stroke and death.

New treatment and improvement of existing therapies for AF are being currently proposed and clinically evaluated at breathtaking speed. Today, the only treatment of AF that is associated with improved survival is continuous oral anticoagulation (aspirin).

Aiming to define new research perspectives and identify unresolved clinical issues in the diagnosis and treatment of AF, the European Heart Rhythm Society (EHRA)3 and the German Atrial Fibrillation Network (AFNET) have invited a panel of international experts on AF as well as representatives from European regulatory bodies such as the European Medicines Agency (EMEA) and the Food and Drug Administration (FDA) and representatives from pharmaceutical industries to meet at the European Heart House in Sophia Antipolis, France, headquarters for the European Society of Cardiology2, on 26 October 2008. This will be the second joint conference organised by EHRA and AFNET4.

Among the topics included in the agenda for this meeting, experts will discuss: anticoagulation in patients at intermediate stroke risk; new concepts for rhythm control drug treatment; what do to if pulmonary vein isolation fails; relevance and intensity of ECG monitoring in clinical practice; relevance of clinically identifiable risk factors for AF progression; what causes the first episode of "idiopathic" AF, and novel therapeutic goals for AF treatment.

Based on all available information, the panel will define perspectives for diagnostic classifications and new therapeutic options. The output from this consensus conference will include suggestions for urgent clinical studies. Conclusions will be summarized in a position paper to guide research on the development of better clinical diagnosis and treatment of AF.


'/>"/>

Contact: Jacqueline Partarrieu
jpartarrieu@escardio.org
33-492-948-627
European Society of Cardiology
Source:Eurekalert

Related biology news :

1. UTSA hosts North American Energy Summit May 1-2
2. NAS to hold 2-day summit on energy issues
3. Global warming and other research from UCLA summit featured in journal
4. Mountain summits in the Alps becoming increasingly similar
5. Cornell will host the Northeast Biofuel Summit, Nov. 11-13
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
(Date:3/16/2017)... - Against identity fraud with DERMALOG solutions "Made in Germany "  ... ... multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today announces that it ... insights to support its reporting, help direct future campaigns, and share ... charity will be using Brandwatch Analytics social listening and analytics technology ... the topics and issues that are a priority for its supporters. ... "Until recently we,ve ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... YORK , March 27, 2017 ... developing novel therapies for neurodegenerative diseases, including Alzheimer,s ... that its application to list the Company,s common ... approved by The NASDAQ Stock Market, a unit ... the listing, Neurotrope will ring the Opening Bell at ...
(Date:3/24/2017)... YORK , March 24, 2017 ... ended the trading session at 5,817.69, down 0.07%; the ... at 20,656.58; and the S&P 500 closed at 2,345.96, ... as 4 sectors closed in green, 4 sectors finished ... day. This Friday, Stock-Callers.com has initiated reports coverage on ...
(Date:3/23/2017)... Research and Markets has announced the ... to their offering. ... The Global Market for Bioproducts Should Reach ... a CAGR of 8.9%, This research report ... seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen ... the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff ... of Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, ...
Breaking Biology Technology: